StockNews.AI
ASBP
StockNews.AI
91 days

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

1. Aspire begins Phase I trial for fast-acting high-dose aspirin formulation. 2. Topline data expected in early Q3 2025 supporting potential FDA approval. 3. Dosing first patient marks key milestone in Aspire's drug development. 4. Trial evaluates safety and pharmacokinetics in healthy volunteers. 5. Innovative delivery system aims for rapid absorption bypassing the GI tract.

7m saved
Insight
Article

FAQ

Why Bullish?

The commencement of the Phase I trial indicates progress in drug development, similar to historical biotech successes that saw substantial stock price increases following pivotal trial announcements.

How important is it?

The article details critical stages of drug front development, impacting investor sentiment and stock performance.

Why Short Term?

Topline data release expected in Q3 2025 may lead to immediate market reactions, as seen in previous biotech stocks that rallied around similar announcements.

Related Companies

AMGNPFEJNJ
Trial marks key milestone in driving pipeline progressPhase 1 trial scheduled for completion mid-June 2025Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that the first patient has been dosed in its Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder and granules when administered orally in healthy adult volunteers. The Phase 1 "crossover" clinical trial, which is being conducted in the United States, will compare the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers administered a sublingual dose of 162.5 mg aspirin powder or granules with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post dose.) This trial will also provide important data about TxB2 and its anti-coagulant bioavailability in the volunteers. For additional information on this trial please visit www.clinicaltrials.gov.The Company expects to disclose topline data from its high-dose aspirin trial early in the third quarter and if successful, this trial has the potential to support accelerated approval, subject to FDA review."Dosing the first patient in our oral transmucosal fast-acting high-dose aspirin formulation study is an important milestone for Aspire as we continue the clinical development of our lead product candidate," said Kraig Higginson, Chief Executive Officer of Aspire. "We are proud that our aspirin formulation is one step closer to our goal of addressing several key unmet needs, and we are grateful to our patients for participating in this trial."About the Aspire Targeted Oral Delivery PlatformAspire's technology delivers a soluble, fast acting granular or powder form drug formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technologies new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream. The benefits of "rapid absorption" are to provide nearly instant treatment impact and high dose absorption. The Company's patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract, and potentially provide an improved treatment outcome.About Aspire Biopharma, Inc.Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.Safe Harbor StatementCertain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.Aspire Biopharma Holdings, Inc.ContactTraDigital IRKevin McGrath+1-646-418-7002[email protected]SOURCE: Aspire Biopharma Holdings, Inc.

Related News